Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocacy for global access.
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
received:
13
11
2023
revised:
29
11
2023
accepted:
02
01
2024
medline:
21
4
2024
pubmed:
21
4
2024
entrez:
20
4
2024
Statut:
ppublish
Résumé
In the current issue of Kidney International, Sinha et al. present data from an open-label, noninferior, randomized controlled trial comparing 12-months of alternate-day prednisolone, given daily during infection, versus levamisole, in children with frequently relapsing or steroid-dependent nephrotic syndrome. This study suggests that both of these strategies are efficacious and safe. Results of this study should redefine the role of levamisole in future guidelines, and a call for global availability of levamisole should be advocated.
Identifiants
pubmed: 38642993
pii: S0085-2538(24)00095-4
doi: 10.1016/j.kint.2024.01.030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
932-934Informations de copyright
Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.